Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone Injection in Patients With Prader-Willi Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03554031
Recruitment Status : Unknown
Verified May 2018 by GeneScience Pharmaceuticals Co., Ltd..
Recruitment status was:  Recruiting
First Posted : June 12, 2018
Last Update Posted : June 12, 2018
Sponsor:
Collaborators:
Children's Hospital of Fudan University
Tongji medical college huazhong university of science & technology
Beijing Children's Hospital
Peking University First Hospital
Peking Union Medical College Hospital
The Children's Hospital of Zhejiang University School of Medicine
Information provided by (Responsible Party):
GeneScience Pharmaceuticals Co., Ltd.

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Unknown
Estimated Primary Completion Date : January 2020
Estimated Study Completion Date : January 1, 2020